Pag. 68
Bibliografia
1. Bohan A, Peter JB. Polymyositis and dermatomyositis. N Engl J Med. 1975, Vol. 292, 344-47, 403-07.
2. Doria A, Gambari P. Polimiosite - Dermatomiosite. [aut. libro] Todesco.
Malattie reumatiche quarta edizione. s.l. : McGrow-Hill, 2007.
3. Dalakas MC. Polymyositis, dermatomyositis and inclusion-body myositis. N Engl J Med. 1991, Vol. 325, 1487-98.
4. Medsger TA Jr, Dawson WN Jr, Masi AT. The epidemiology of polymyositis.
Am J Med. 1979, Vol. 48, 715-23.
5. Van der Meulen MF, Bronner IM, Hoogendijk JE, et al. Polymyositis an overdiagnosed entity. Neurology. 2003, Vol. 61, 316-321.
6. Bohan A et al. A computer-assisted analysis of 153 patients whith polymyositis and dermatomyositis. Medicine (Baltimore). 1977, Vol. 56, 255-286.
7. Hill CL, Zhang Y, et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet. 2001, Vol. 357, 96-100.
8. Arnett FC, Targoff IN, Mimori T, et al. Interrelationship of major histocompatibility complex class II alleles and autoantibodies in four ethnic groups with various forms of myositis. Arthritis and Rheumatism. 1996, Vol. 39, 1507-1518.
9. Love LA, et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups.
Medicine (Baltimore). 1991, Vol. 70, 360-374.
10. Sekul EA, Dalakas MC. Inclusion body myositis: new concepts. Semin Neurol.
1993, Vol. 13, 256-263.
Pag. 69 11. Ramanan AV, Feldman BM. Clinical features and outcomes of juvenile dermatomyositis and other childhood onset myositis syndromes. Rheum Dis Clin N Am.
2002, Vol. 28, 833-857.
12. Dalakas MC. Polimiosite, dermatomiosite e miosite da corpi inclusi. Harrison - Principi di medicina interna 15°edizione. s.l. : MCGrow-Hill, 2002.
13. Shamim EA, Rider LG, Miller FW. Update on the genetics of the idiopathic inflammatory myopathies. Curr Opin Rheumatol. 2000, Vol. 12, 482-91.
14. Koffman BM, Sivakumar K, Simonis T, Stroncek D, Dalakas MC. HLA allele distribution distinguishes sporadic inclusion body myositis from hereditary inclusion body myopathies. J Neuroimmunol. 1998, Vol. 84, 139-42.
15. Dalakas MC. Therapeutic targets in patients with inflammatory myopathies:
Present approaches and a look to the future. Neuromuscolar Disorders. 2006, Vol. 16, 223-236.
16. Hilton-Jones D. Inflammatory myopathies. Curr Opin Neurol. 2001, Vol. 14, 591-6.
17. Arahata K, Engel AG. Monoclonal antibody analysis of mononuclear cells in myopathies. I. Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibres invaded by T cells. Annals of Neurology.
1984, Vol. 16, 193-208.
18. Emslie-Smith AM, Engel AG. Microvascular changes in early and advanced dermatomyositis: a quantitative study. Annals of Neurology. 1990, Vol. 27, 343-56.
19. Kissel JT, Mendell JR, Rammohan KW. Microvascular deposition of complement membrane attack complex in dermatomyositis. N Engl J Med. 1986, Vol.
314, 329-34.
Pag. 70 20. Wiendl H, Hohlfeld R, Kieseier BC. Immunobiology of muscle: advances in understanding an immunological microenvironment. Trends Innunol. 2005, Vol. 26, 373-80.
21. Nagaraju K, et al. Conditional up-regulation of MHC class I in skeletal muscle leads to self-sustaining autoimmune myositis and myositis-specific autoantibodies.
Proceedings of the National Academy of Sciences USA. 2000, Vol. 97, 9209-14.
22. Bender A, Behrens L, Engel AG, Hohlfeld R. T-cell heterogeneity in muscle lesions of inclusion body myositis. J Neuroimmunol. 1998, Vol. 84, 86-91.
23. Dalakas MC. Inflammatory disorders of muscle: progress in polymyositis, dermatomyositis and inclusion body myositis. CurrOpin Neurol. 2004, Vol. 17, 561-7.
24. Askanas V, Engel WK. Sporadic inclusion-body myositis and hereditary inclusion-body myopathies: current concepts of diagnosis and pathogenesis. Curr Opin Rheumatol. 1998, Vol. 10, 530-42.
25. Mikol J, Engel AG. Inclusion body myositis. [aut. libro] Franzini-Armstrong Engel. Myology 3rd edition 1367-88. New York : McGrawHill, 1998.
26. Targoff IN, Miller FW, Medsger TA Jr, Oddis CV. Classification criteria for the idiopatic inflammatory myopathies. Current Opinion in Rheumatology. 1997, Vol.
9, 527-535.
27. Dalakas MC, Hohlfeld R. Polymyiositis and dermatomyositis. The Lancet.
2003, Vol. 362, 971-982.
28. Rider LG, Giannini EH, et al. Defining Clinical Improvement in Adult and Juvenile Myositis. J Rheumatol. 2003, Vol. 30, 603-17.
29. Huber AM, Feldman BM, Rennebohm RM, et al - Juvenile dermatomyositis desease activity collaborative study group. Validation and clinical significance of the Childhood Myositis Assessment Scale for assessment of muscle
Pag. 71 function in the juvenile idiopathic inflammatory myopathies. Arthritis Rheum. 2004, Vol. 50, 1959-1603.
30. Dalakas MC. Calcifications in dermatomyositis. N Engl J Med. 1995, Vol. 333, 978.
31. Oddis CV, Medsger TA Jr, Cooperstein LA. A subluxing arthropathy associated with the anti-Jo-1 antibody in polymyositis/dermatomyositis. Arthritis and Rheumatism. 1990, Vol. 33, 1640-5.
32. Sontheimer RD. Dermatomyositis: an overview of recent progress with emphasis on dermatologic aspects. Dermatol Clin. 2002, Vol. 20, 387-408.
33. Otero C, Illa I, Dalakas MC. Is there dermatomyositis (DM) without myositis? Neurology. 1992, Vol. 42, 388.
34. Drake LA, Dinehart SM, et al. Guidelines of care for dermatomyositis.
American Academy of Dermatology. Journal of the American Academy of Dermatology.
1996, Vol. 34, 824-9.
35. Garton MJ, Isenberg DA. Clinical features of lupus myositis versus idiopathic myositis: a review of 30 cases. British Journal of Rheumatology. 1997, Vol. 36, 1067- 74.
36. Parker P, Chao NJ, Ben-Ezra J, et al. Polymyositis as a manifestation of chronic graft-versus-host disease. Medicine (Baltimore). 1996, Vol. 75, 279-85.
37. Spiera R, Kagen L. Extramuscolar manifestation in idiopathic inflammatory myopathies. Current Opinion in Rheumatology. 1998, Vol. 10, 556-61.
38. Dietz F, Logeman JA, Sahgal V, Schmid FR. Cricopharyngeal muscle dysfunction in the differential diagnosis of dysphagia in polymyositis. Arthritis Rheum.
1980, Vol. 23, 491-95.
Pag. 72 39. de Merieux P, Verity MA, Clements PJ, Paulus HE. Esophageal abnormalities and dysphagia in polymyositis and dermatomyositis: clinical, radiographic and pathologic features. Arthritis Rheum. 1983, Vol. 26, 961-68.
40. Marie I, Hatron PY, et al. Influence of age on characteristics of polymyositis and dermatomyositis in adults. Medicine (Baltimore). 1999, Vol. 78, 139-47.
41. Haupt HM, Hutchins GM. The heart and cardiac conduction system in polymyositis-dermatomyositis: a clinicopathologic study of 16 autopsied patients. Am J Cardiol. 1982, Vol. 50, 998-1006.
42. Quartier P, Bonnet D, Fournet JC, et al. Severe cardiac involvement in children with systemic sclerosis and myositis. J Rheumatol. 2002, Vol. 29, 1767-73.
43. Lakhanpal S, Lie JT, Conn DL, Martin WJ. Pulmonary disease in polymyositis/dermatomyositis: a clinicopathological analysis of 65 autopsy cases. Ann Rheum Dis. 1987, Vol. 46, 23-29.
44. Douglas WW, Tazelaar HD, Hartman TE, et al. Polymyositis dermatomyositis associated interstitial lung disease. Am J Respir Crit Care Med. 2001, Vol. 164, 1182-85.
45. Hirakata M, Nagai S. Interstitial lung disease in polymyositis and dermatomyositis. Curr Opin Rheumatol. 2000, Vol. 12, 501-08.
46. Clawson K, Oddis CV. Adult respiratory distress syndrome in polymyositis patients with the anti-Jo-1 antibody. Arthritis and Rheumatism. 1995, Vol. 38, 1519-23.
47. Hilton-Jones D, Squier MV. Risk of cancer in dermatomyositis and polymyositis (letter). N Engl J Med. 1992, Vol. 327, 207.
48. Dorph C, Lundberg IE. Idiopatic inflammatory myophaties - Myositis. Best practice and research clinical rheumatology. 2002, Vol. 16, 817-832.
Pag. 73 49. Chow WH, Gridley G, et al. Cancer risk following polymyositis and dermatomyositis: nationwide cohort study in Denmark. Cancer causes and control.
1995, Vol. 6, 9-13.
50. Airio A, Pukkala E, Isomäki H. Elevated cancer incidence in patiens with dermatomyositis: population based study. Journal of Rheumatology. 1995, Vol. 22, 1300-1303.
51. Chen YJ, Wu CY, Shen JL. Predicting factors of malignancy in dermatomyositis and case control study. British journal of dermatology. 2001, Vol. 144, 825-31.
52. Callen JP. When and how should the patient with dermatomyositis or amyopathic dermatomyositis be assessed for possible cancer? Arch. Dermatol. 2002, Vol. 138, 969-71.
53. Bohlmeyer TJ, Wu AH, Perryman MB. Evaluation of laboratory tests as a guide to diagnosis and therapy of myositis. Theum Dis Clin N Am. 1994, Vol. 20, 845- 856.
54. Dayal NA, Isenberg DA. Assessment of inflammatory myositis. Current Opinion in Rheumatology. 2001, Vol. 13, 488-92.
55. Rider LG, Miller FW. Idiopatic inflammatory muscle disease: clinical aspects.
Bailliere's CLin Rheumatol. 2000, Vol. 14, 37-54.
56. Romagnani S, Emmi L, Almerigogna F. Polimiosite e dermatomiosite.
Malattie del sistema immunitario - pag 272-277. s.l. : MCGrow-Hill, 1995.
57. Uncini A, Lange DJ, Lovelace RE, et al. Long-duration polyphasic motor unit potentials in myopathies: a quantitative study with pathological correlation. Muscle nerve. 1990, Vol. 13, 263-67.
Pag. 74 58. Johnsen B, Fuglsang-Frederiksen A, et al. Inter and Intraobserver valuation in the interpretation of electromyographic tests. ElectromyographyClin Neurophysiolohy. 1995, Vol. 97, 432-443.
59. RJ, Seidman. Muscle biopsy and the pathology of skeletal muscle. eMedicine.
2006.
60. Dalakas MC. Muscle biopsy findings in inflammatory myopathies. Rheum Dis Clin N Am. 2002, Vol. 28, 779-98.
61. Engel AG, Hohlfeld R, Banker BQ. The polymyositis and dermatomyositis syndromes. [aut. libro] Franzini-Armstrong Engel. Myology 2nd edition 1335-83. New York : MCGrow-Hill, 1994.
62. Hohlfeld R, Engel AG. The immunobiology of muscle. Immunol today. 1994, Vol. 15, 269-74.
63. Dalakas MC. Immunopathogenesis of inflammatory myophaties. Ann Neurol.
1995, Vol. 37, 74-86.
64. Bartlett ML, Ginn L, Beitz L, et al. Quantitative assessment of myositis in thigh muscle using magnetic resonance imaging. Magn Reson Imaging. 1999, Vol. 17, 183-191.
65. Adams EM, Chow CK, Premkumar A, et al. The idiopathic inflammatory myopathies: spectrum of MR findings. Radio-Graphics. 1995, Vol. 15, 563-74.
66. Yosipovitch G, Beniaminov O, et al. STIR magnetic resonance imaging: a non-invasive method for detection and follow-up of dermatomyositis. Arch Dermatol.
1999, Vol. 135, 721-2.
67. Cantwell C, Ryan M, O'Connell M, et al. A comparison of inflammatory myopathies at whole-body turbo STIR MRI. Clinical Radiology. 2005, Vol. 60, 261- 267.
Pag. 75 68. Greco A, McNamara MT, Escher RM, et al. Spin-echo and STIR MR imaging of sports related muscle injuries at 1.5T. j ComputAssist Tomogr. 1991, Vol.
15, 994-999.
69. Steinbach LS, Tehranzadeh J, et al. Human immunodeficiency virus infection: musculoskeletal manifestations. Radiology. 1993, Vol. 186, 833-838.
70. May DA, Disler DG, Jones EA, et al. Abnormal Signal Intensity in Skeletal Muscle at MR Imaging: Patterns, Pearls, and Pitfalls. RG. 2000, Vol. 20, Special Issue.
71. Feldman F, Zwass A, Staron RB, Haramati N. MRI of soft tissue abnormalities: a primary cause of sickle cell crisis. Skeletal Radiol. 1993, Vol. 22, 501- 506.
72. Resnick D. Disorders due to medications and other chemical agents. [aut. libro]
Resnick. Diagnosis of bone and joint disorders 3rd edition - 3309-3342. Philadelphia : Saunders, 1995.
73. Jing Q, Olsen NJ, et al. Diffusion-weighted imaging of inflammatory myopathies: polymyositis and dermatomyositis. Magn Reson. 2008, Vol. 27, 212-217.
74. Tanimoto K, Nakano K, Kano S, et al. Classification criteria for polymyositis and dermatomyositis. Journal of Rheumatology. 1995, Vol. 22, 668-674.
75. Miller FW, Rider LG, Plotz PH, et al. Diagnostic criteria for polymyositis and dermatomyositis (letter). The Lancet. 2002, Vol. 362, 1762.
76. Sanmarti R, Collado A, Gratacos J. Reduced activity of serum creatine kinase in rheumatoid arthritis: a phenomenon linked to the inflammatory response. Br J Rheumatol. 1994, Vol. 33, 231-234.
77. Rider LG, Feldman BM, et al. Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies: I. Physician, parent, and patient global assessments. Arthritis Rheum. 1997, Vol. 40, 1976-83.
Pag. 76 78. Wong EH, Hui AC, Griffith JF, et al. MRI in biopsy-negative dermatomyositis. Neurology. 2005, Vol. 64, 750-.
79. Dalakas MC. How to diagnose and treat the inflammatory myopathies. Semin Neurol. 1994, Vol. 92, 365-69.
80. —. IVIg in other autoimmune neurological disorders: current status and future prospects. J Neurol. 2008, Vol. 255, 12-16.
81. Mastaglia FL, Phillips BA, Zilko PJ. Immunoglobulin therapy in inflammatory. J Neurol Neurosurg Psychiatry. 1998, Vol. 65, 107-110.
82. Dalakas MC, Illa I, Dambrosia JM, et al. A controlled trial of highdose intravenous immunoglobulin infusions as treatment for dermatomyositis. N Engl J Med.
1993, Vol. 329, 1993-2000.
83. Miller FW, Leitman SF, Cronin ME, et al. A randomized doubleblind controlled trial of plasma exchange and leukapheresis in patients with polymyositis and dermatomyositis. N Engl J MEd. 1992, Vol. 326, 1380-84.
84. Alexanderson H, Stenström CH, et al. The safety of a resistive home exercise program in patients with recent onset active polymyositis or dermatomyositis.
Scandinavian Journal of Rheumatology. 2000, Vol. 29, 295-301.
85. Maugars YM, Berthelot JM, Abbas AA, et al. Long-term prognosis of 69 patients with dermatomyositis or polymyositis. Clin Exp Rheumatol. 1996, Vol. 14, 263-74.
86. Marie I, Hachulla E, Hatron PY, et al. Polymyositis and dermatomyositis:
short term and longterm outcome, and predictive factors of prognosis. J Rheumatol.
2001, Vol. 28, 2230-37.
87. Airo A et al. Prognosis and mortality of polymyositis and dermatomyositis patiens. Clin Rheumatol. 2006, Vol. 25, 234-239.
Pag. 77 88. Torres C et al. Survival, mortality and causes of death in inflammatory myopathies. Autoimmunity. 2006, Vol. 39(3), 205-215.
89. Dankó K, Ponyi A, Constantin T, Borgulya G, Szegedi G. Long-term survival of patients with idiopathic inflammatory myopathies according to clinical features: a longitudinal study of 162 cases. Medicine (Baltimore). 2004, Vol. 83, 35-42.
90. Crum-Cianflone NF. Bacterial, fungal, parasitis and viral myositis. Clin Microbiol Rev. 2008, Vol. 21, 473-94.
91. Hargaden G, O'Connell M, et al. Current conceps in whole-body imaging using turbo short tau inversion recovery MR inaging. Am J Roentgenol. 2003, Vol. 180, 247-52.
92. Hargaden G, O’Connell M, Kavanagh E, Powell T, Ward R,. Current concepts in whole-body imaging using turbo short tau inversion recovery MR imaging.
Am J Roentgenol. 2003, Vol. 180, 247-52.
93. Sigurgeirsson, Lindelöf, Edhag, Allander. Risk of cancer in patients with dermatomyositis or polymyositis: a population-based study. N Engl J Med. 1992, Vol.
326, 363-67.
94. Buchbinder R, Forbes A, et al. Incidence of malignant disease in biopsy proven inflammatory myopathy. A population-based cohort study. Annals of Internal Medicine. 2001, Vol. 134, 1087-95.
